Intrafamilial Phenotypic Variability of Collagen VI-Related Myopathy Due to a New Mutation in the COL6A1 Gene

Sergey N Bardakov, Roman V Deev, Raisat M Magomedova, Zoya R Umakhanova, Valérie Allamand, Corine Gartioux, Kamil Z Zulfugarov, Patimat G Akhmedova, Vadim A Tsargush, Angelina A Titova, et al.

To cite this version:
Sergey N Bardakov, Roman V Deev, Raisat M Magomedova, Zoya R Umakhanova, Valérie Allamand, et al.. Intrafamilial Phenotypic Variability of Collagen VI-Related Myopathy Due to a New Mutation in the COL6A1 Gene. Journal of Neuromuscular Diseases, 2020, pp.1-12. 10.3233/JND-200476. hal-03094479

HAL Id: hal-03094479
https://hal.sorbonne-universite.fr/hal-03094479
Submitted on 4 Jan 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Intrafamilial Phenotypic Variability of Collagen VI-Related Myopathy Due to a New Mutation in the COL6A1 Gene

Sergey N. Bardakov\textsuperscript{a,\ast}, Roman V. Deev\textsuperscript{b,c}, Raisat M. Magomedova\textsuperscript{d}, Zoya R. Umakhanova\textsuperscript{d}, Valérie Allamand\textsuperscript{e}, Corine Gartioux\textsuperscript{e}, Kamil Z. Zulfugarov\textsuperscript{d}, Patimat G. Akhmedova\textsuperscript{d}, Vadim A. Tsargush\textsuperscript{a}, Angelina A. Titova\textsuperscript{f}, Mikhail O. Mavlikeev\textsuperscript{f}, Vadim L. Zorin\textsuperscript{b}, Ekaterina N. Chernets\textsuperscript{c}, Gimat D. Dalgatov\textsuperscript{g}, Fedor A. Konovalov\textsuperscript{b} and Artur A. Isaev\textsuperscript{b}

\textsuperscript{a}S.M. Kirov Military Medical Academy, St. Petersburg, Russia
\textsuperscript{b}Human Stem Cells Institute, Moscow, Russia
\textsuperscript{c}I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russia
\textsuperscript{d}Dagestan State Medical Academy, Makhachkala, Russia
\textsuperscript{e}Sorbonne Université UPMC Paris 06 – Inserm UMRS974, Research Center in Myology, Hospital Pitié-Salpêtrière, Paris, France
\textsuperscript{f}Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan, Russia
\textsuperscript{g}Scientific-Clinical Center of Otorhinolaryngology FMBA of Russia Moscow, Russia
\textsuperscript{h}Independent Clinical Bioinformatics Laboratory, Moscow, Russia

Abstract. A family of five male siblings (three survivors at 48, 53 and 58 years old; two deceased at 8 months old and 2.5 years old) demonstrating significant phenotypic variability ranging from intermediate to the myosclerotic like Bethlem myopathy is presented. Whole-exome sequencing (WES) identified a new homozygous missense mutation chr21:47402679 \(T>C\) in the canonical splice donor site of the second intron (c.227 + 2T>C) in the \textit{COL6A1} gene. mRNA analysis confirmed skipping of exon 2 encoding 925 amino-acids in 94–95% of resulting transcripts. Three sibs presented with intermediate phenotype of collagen VI-related dystrophies (48, 53 and 2.5 years old) while the fourth sibling (58 years old) was classified as Bethlem myopathy with spine rigidity. The two older siblings with the moderate progressive phenotype (48 and 53 years old) lost their ability to maintain a vertical posture caused by pronounced contractures of large joints, but continued to ambulated throughout life on fully bent legs without auxiliary means of support. Immunofluorescence analysis of dermal fibroblasts demonstrated that no type VI collagen was secreted in any of the siblings’ cells, regardless of clinical manifestations severity while fibroblast proliferation and colony formation ability was decreased. The detailed genetic and long term clinical data contribute to broadening the genotypic and phenotypic spectrum of \textit{COL6A1} related disease.

Keywords: Ullrich congenital muscular dystrophy, fibroblasts, contractures, myosclerotic phenotype of Bethlem myopathy, collagenopathy, type VI collagen, leaky splicing, \textit{COL6A1}

INTRODUCTION

Collagen VI-related myopathies are among the most frequently identified forms of congenital muscular dystrophies, including Bethlem myopathy (BT...
HLM1, Bethlem myopathy 1, OMIM # 158810),
Ulrich myopathy (UCMD 1, Ulrich congenital mus-
cular dystrophy 1, OMIM # 254090) and a number
of intermediate clinical phenotypes [1, 2]. Collagen
VI-related muscular dystrophies are the second most
common form of congenital muscular dystrophy in
Europe, Japan and Australia. For instance, the preva-
ience rate of UCMD and Bethlem myopathy in north-
ern England is 0.13 and 0.77 per 100,000 population,
respectively [3, 4]. Collagen VI-related myopathies
form a single continuum, the most severe type of
which is UCMD [5–7]. UCMD is characterized by an
early onset, often from birth, manifesting as muscle
weakness and hypotonia, proximal joint contractures,
distal joint hypermobility, as well as a number of bone
deforizations such as kyphoscoliosis and torticollis.
The mildest form of collagen VI-related myopathies
is classical BTHLM characterized by distal as well
as proximal contractures, proximal muscle weakness
and remaining ambulation into adulthood [8, 9]. In
addition, two opposing variants for BTHLM have
been described: limb-girdle phenotype is character-
ized by late or no contractures [6] and myosclerotic
myopathy is characterized by early, diffuse, progres-
sive contractures resulting in severe limitation of
movement of axial, proximal and distal joints [7, 10].
The CK activity level is either unchanged, or 1.5 –
2-fold increased [11].

Collagen VI-related myopathies are caused by
dominant as well as recessive mutations in COL6A1,
COL6A2 (21q22.3) and COL6A3 (2q37) genes, en-
coding for the corresponding subunits of type VI col-
lagen: α1 (VI), α2 (VI), α3 (VI) [9, 12, 13].

In skeletal muscles type V collagen provides inter-
action between muscle basement membranes and
the extracellular matrix and is known to bind biglycan,
types I and IV collagen and decorin [14]. In addition,
disrupted induction of autophagy and the develop-
ment of mitochondrial mediated apoptosis with a d
in myofibers has been reported in a mouse model of
deficiency of α1 (VI) [15, 16].

UCMD may be caused by recessive inheritance
due to homozygous or compound heterozygous muta-
tions; however, dominantly acting mutations in
COL6A1 COL6A2 and COL6A3 have also been
described and may be more common, in particular de
novo mutations. [17, 18]. Although the typical genetic
mechanism of inheritance for Bethlem myopathy is
dominant, recessive mutations have also been seen in
patients [19–21]. An autosomal recessive inheritance
mode has also been described specifically for the rare
myosclerotic variant of BTHLM [7].

Inter-, intrafamilial, intergenerational phenotypic
variability and disease progression in collagen VI-
related myopathies are common. One of the reasons
described for phenotypic variability is sporadic and
parental mosaicism of dominantly acting collagen VI
heterozygous mutations [22–24]. However, no sig-
ificant phenotypic variability among siblings with
homozygous mutations in the COL6A1 gene has
been reported previously. We present the results of a
familial observation of five siblings (aged 8 months,
2.5, 43, 53, 58 years) with distinct phenotypic vari-
ability (intermediate phenotype and BTHLM with
spine rigidity) due to a new homozygous mutation
in COL6A1. We undertook an in-depth compari-
son of phenotypic differences in three sibs (43, 53,
58 years old). We also describe remarkable
adaptive changes at the late stage of the disease
which allowed two siblings (43 and 53 years old)
to continue ambulation throughout life on fully bent
legs.

PATIENTS AND METHODS

Examinations

Examinations and tests were performed after in-
formed consent was obtained. There was documented
consanguinity of the parents in generation II in this
Avarian family in Dagestan. Three out of five affected
male siblings in generation III (Patient III:1, 48 years
old, Patient III:2, 53 years old, and Patient III:3, 58
years old) with clinical manifestations of collagen
VI-related myopathy were examined between 2016
and 2018. The two other affected siblings were not
personally examined (Patient III:11, presented with
floppy baby syndrome and died of respiratory failure
at 8 months old, Patient III:12 with early-onset severe
proximal joint contractures and distal joint hypermobility and died as a result of a head
injury at 2.5 years old) (Fig. 1). We present here
the results of the most current examination of the
three surviving siblings along with data from medical
records.

Laboratory tests and investigations

Serum CK level were determined in all patients,
X-rays of knee and ankle joints, spirography, ECG,
echocardiography, EMG, MRI of pelvic and lower
extremity muscles (T1-, T2-WI, T2-FatSat) were per-
formed in all patients.
Fig. 1. Pedigree of the siblings’ family. Symbols in black represent sick family members; exclamation mark - family members personally examined by the author; mt – mutant allele; wt – wild type allele. The position of siblings when walking (a – Patient III:1, 48 years old, b – Patient III:2, 53 years old). The phenotype of siblings (Patient III:1, 48 years old – c, d, e, f, g, h, i; Patient III:2, 53 years old – J, k, l, m, n, o, p; Patient III:3, 58 years old – q, r, s, t, u, v, w). Written informed consents of patients are on file.

Genetic testing

Whole-exome sequencing (WES) was performed on DNA samples obtained from Patient III:1, III:2, III:3 using a pair-end method (2 × 90 base pairs) on the Illumina HiSeq 2000 platform using the SureSelectV4 target sequences enrichment system (51M). The average reading depth was 85× in all samples. Potentially pathogenic variants were identified in comparison with reference human genome databases and the changes detected were confirmed by standard methods (Sanger sequencing and PCR). Segregation analysis of the identified mutations was performed in the mother (II:2) of the siblings.
Primary dermal fibroblast culture

Biopsy samples (4 mm³) were taken from the skin behind-the-ear of patients III:1, III:2, and III:3 under local anesthesia (2% lidocaine solution). The biopsy samples were treated with 0.05% type II collagenase (Sigma, USA) at 37°C for 12 hours, then centrifuged at 200 g for 10 min. The cell pellet was resuspended and cultured in DMEM (Sigma, USA) supplemented with 10% fetal bovine serum (FBS) (HyClone, USA), and 20 μg/ml gentamicin (Sigma, USA) at 37°C 5% CO₂. Skin fibroblasts of a 35-year-old healthy male were used as the control.

Fibroblast colony-formation efficacy (CFE-F)

CFE-F was evaluated at passage 1 under the standard procedure. The cell suspension was split into three 100 mm Petri dishes to obtain a clonal inoculum density of 3–4 cells/cm² in DMEM (Sigma, USA) supplemented with 10% FBS (HyClone, USA), and 20 μg/ml gentamicin (Sigma, USA). The Petri dishes were incubated in a CO₂-incubator under saturated humidity conditions at 37°C in the 5% CO₂ atmosphere for 14 days. Thereafter, the culture dishes with the pre-formed colonies were washed three times with PBS (pH 7.4) and fixed with 70% alcohol for 15 minutes at room temperature. Then alcohol residuals were removed by triple washing with distilled water, and the colonies were stained with a KaryoMAX® Giemsa Stain Stock Solution (Gibco, USA) at 37°C for 20 minutes. The dishes with stained colonies were thoroughly washed from excessive stain and dried at room temperature for 5–7 hours. Formed colonies were counted, the number and shape of their constituent cells determined. A total number of 15 explanted cells in counted colonies only was more than 20. CFE-F was calculated according to the Fridenshtein’s equation for stromal progenitor cells: a pre-formed colonies to explanted cells ratio was multiplied by 100%. CFE-F values reflect individual fibroblast progenitor cell counts. When the colony formation efficacy ranges from 45 to 49% in men and from 36 to 45% in women, the regenerative potential is considered normal [25–27].

Fibroblast proliferative potential

All fibroblasts colonies were classified as dense, diffuse and mixed ones. The fibroblast proliferative potential (a proliferative index) was calculated by a colony distribution (dense, diffuse, mixed) using the formula: PI = [1 (DC)+2 (MC)+3 (DC1)]/100% [26, 27], where PI is the proliferative index, DC – diffuse colonies, (%), MC – mixed colonies, (%), DC1 – dense colonies, (%). The proliferative potential depends on the number of mitotically active cells in the culture, which determines the rate of regenerative processes in the dermis. The proliferative potential of dermal fibroblasts is higher in denser colonies and less in diffuse ones. When the proliferative index ranges from 2.0 to 2.4 in men and from 1.8 to 2.0 in women, the proliferative potential is considered normal.

Immunofluorescent staining of skin-derived fibroblasts

Collagen VI was stained on confluent cells cultured with 0.25 mM ascorbic acid as previously reported by Hicks et al. (2008), and triton X-100 to permeabilize the cells in order to detect intracellular retention of COLVI [28]. Fibroblasts were incubated with collagen VI polyclonal antibodies (abcam, Ab6588, dilution – 1:1000). Fluorescence was detected under an AxioPlan 2 microscope (Zeiss, Germany) equipped with the HBO 100 mercury lamp (Zeiss). Single channel images and overlays were captured using the Metavue software (Molecular Devices).

Transcript analysis

Total RNA was extracted from fibroblast cultures using the ReliaPrep™ RNA Cell Miniprep System kit (Promega, France) and reverse transcribed to cDNA with the Superscript RTIII kit (LifeTechnologies SAS, France) following the manufacturer’s recommendations. cDNA samples were subjected to PCR amplification using primers located in exons 1 and 3 of the COL6A1 gene (5’-ACCGTTAGTATGC GAGTTTCTGGCTGGGAGCAGGA-3’ and 5’-TC GGATAGTCACTGGTTATAGCCAGTCGGTGT A-3’, respectively). RPLP0 was used as reference gene (5’-ATGTGGGCTTTGTGTTTACCCPR-3’ and 5’-TCCAGTCTTGATCAGCTGCA-3’). PCR products were analysed on 2% agarose gel and semi-quantification was performed using the ImageJ software.

Ethics statement

All procedures were performed after the patients signed an informed consent form as required by the
Table 1
Clinical characteristics and pulmonary function parameters of the sibs (Patient III:1, III:2, III:3)

| Characteristic (age of onset, years) | III:1  | III:2  | III:3  |
|-------------------------------------|--------|--------|--------|
| Beginning of independent walking    | 3–4    | 3      | 2.5    |
| Running and jumping                 | Impossible | Impossible | Delay  |
| Muscular weakness                   | 3 (m. quadr. femor. 3/5 MRC) | 3 (m. quadr. femor. 3–4/5 MRC) | 6–7 (m. quadr. femor. 4/5 MRC) |
| Difficulty in stair climbing         | 3–4    | 3–4    | 33     |
| Difficulty in standing up from a sitting position | 6      | 7      | 40     |
| Means of support                    | 7–13 (crutches) | 10–13 (crutches) | Did not use |
| Muscle atrophy                      | Shoulder girdle, upper limbs | Diffuse, shoulder girdle mainly | Shoulder girdle and upper limbs |
| Knee joint contractures             | 3–4    | 3–4    | 7–8    |
| Hip joints contractures             | 3–4    | 3–4    | 7–8    |
| Elbow joint contractures            | 13–14  | 13     | 18–19  |
| Shoulder joint contractures         | 16–18  | 15–16  | 23–25  |
| Wrist joint contractures            | 23–25  | 18     | 30–32  |
| Achilles tendon contractures        | 13     | 13     | 16–17  |
| Joint hypermobility                 | Does not persist | Persists | Persists |
| Dyspnea, years                      | No     | 40     | 40     |
| Pulmonary function parameters (at the last visit) |        |        |        |
| Age at last visit, y.o.             | 48     | 53     | 58     |
| Tidal volume, ml (Δ% of N)          | 200 (50) | 100 (25) | 150 (37.5) |
| VC, ml (Δ%, of proper VC)           | 1400 (39.2) | 1100 (33.8) | 1800 (52.3) |
| Proper VC, ml.                      | 3572   | 3252   | 3444   |
| Inspiratory reserve volume, ml (Δ% of N) | 800 (57) | 700 (50) | 1000 (71) |
| Expiratory reserve volume, ml (Δ% of N) | 400 (40) | 300 (30) | 650 (65) |

Note: 1. VC is the vital capacity of the lungs; 2. Proper VC of the lungs = height (cm) × 0.052 – age (years) × 0.028 – 3.2; 3. N expiratory reserve volume (ERV) – 1000–1400 ml; 4. N inspiratory reserve volume (IRV) – 1400 ml (IRV = VC – (RV + ERV)).

Declarations of Helsinki (2013) and the study protocol (#AC-2348-082018) approved by the local Ethics Committee of the Dagestan State Medical Academy (Russia). All patients signed an informed consent form for publication their medical data and photographs.

Description of clinical cases

All patients were born following normal pregnancies. The parents were second cousins and clinically unaffected. The proband’s father (II:1) died of stomach malignancy at the age of 75 years. The family history is otherwise negative for neuromuscular diseases (Table 1).

Review of history and medical records data for siblings III:1 and III:2 shows evidence of a similar disease onset in 3–4 years old and progression corresponding to the intermediate phenotype of collagen VI-related dystrophies while maintaining the ability to walk with bent knees and thigh joints from the age of 10–13 years (Fig. 1). The eldest sibling (Patient III:3) had a significantly lower rate of progression, the minimal severity of contractures, with a Trendelenburg gait retained and classified as BTHLM.

Clinical neurological examination (at the last visit)

Patient III:2 (53 years old) was extremely thin with a BMI of only 14.9 (less than 15.0: severely underweight). He had the most severe contractures, diffuse muscle atrophy with a tight feel to the muscles (the mid-upper arm circumference (MUAC) – 16/15 cm; normal value for adult men greater than 23 cm [29]), that was a manifestation of intermediate phenotype of collagen VI-related dystrophies with a prominent diffuse contractural component.

The eldest sibling (Patient III:1, 48 years old) had a normal trophic status with a BMI 23.31, but with a similar degree of prominent contractures, he had an earlier and more pronounced proximal muscle weakness and corresponded to intermediate phenotype of collagen VI-related myopathy with the predominance of a myopathic syndrome (MUAC – 22.5/22.0 cm). The eldest sibling (Patient III:3, 58 years old) was very thin with a BMI being 17.01 (16.0–18.49), but with minimal limb contractures except for spinal (axial) rigidity and milder muscle weakness despite atrophic muscles (MUAC – 19/18 cm), overall consistent with a Bethlem phenotype with spinal rigidity.
**Distribution of muscle strength and atrophy**

All examined siblings had muscle weakness predominantly in the flexors of the neck, levators of the scalpula, elbow extensors, digit flexors, thigh adductor muscles, lower leg extensors, and foot adductor muscles (3/5 MRC). Muscle weakness predominated in distal parts of the upper limbs (3–4/5 MRC). It was most pronounced in Patient III:1, and least pronounced in Patient III:3 (Fig. 1).

Muscle atrophy and contractural changes were most intense in Patient III:2 and Patient III:3.

Upper extremity muscle atrophies were diffuse involving deltoid muscles to a least degree, where sclerotic changes resulted in the formation of 3–4 separate bundles (Fig. 3). Muscle atrophy was mainly observed in distal parts of the lower limbs.

Tendon reflexes could not be elicited.

**Skin findings**

Type I follicular hyperkeratosis was most pronounced in Patient III:1, to a lesser extent in Patient III:2, while none observed in Patient III:3. In addition, all siblings had signs of seborrheic dermatitis and did not have abnormal keloid formation (Fig. 3).

**Blood biochemistry**

Serum CK activity was slightly increased (235–280 U/l) in the patients.

**MRI of the lower extremities**

A MRI pattern showed typical signs of perifascial pronounced fatty infiltration, resulting in increased signal on T1 weighted images along the muscle periphery and around the central fascia (in m. rectus femoris), as well as more diffuse involvement of other muscles [30–32].

Fatty replacement was more pronounced in thigh and pelvic girdle muscles than in the calf ones predominantly involving the gluteus and thigh posterior muscles (stage 2B–3, according to E. Mercuri, 2002) [33]. Patients III:1 and III:2 had the most pronounced fatty infiltration. Yet, Patients III:1 and III:2 had a relatively hypertrophic appearance of m. rectus femoris, m. vastus lateralis, m. sartorius, m. semimembranosus, m. semitendinosus and m. biceps femoris caput longus, which thus appeared to be less involved, potentially related or contributing to ambulation with bent hip and knee joints. Patient III:3 had moderate atrophy of m. rectus femoris and m. vastus lateralis (Fig. 2).

**Spirometry**

Spirometry demonstrated a decrease in all basic pulmonary function parameters. The tidal volume was decreased by 50% (200 ml), 75% (100 ml) and 62% (150 ml) in patients III:1, III:2 and III:3, respectively (Table 1). Patients III:2 and III:3 had...
complained of dyspnea independent of body position from the age of 40. However, because of limited access to medical technology none of the patients had initiated non-invasive ventilatory support. Despite the untreated hypoventilation and living at high altitude (about 4100 m above sea level) they were able to maintain physical activity.

**X-ray examination of knee and ankle joints**

The results of X-ray scans showed chronic, knee-joint overloads and elevated patellae (an Insall-Salvati ratio of 1.4) in patients III:1 and III:2. The scans also uncovered signs of osteoarthritis in the ankle joints of patients III:1 and III:2. Lateral
subluxations of the talus bones were combined with wedge-shaped deformations at the tibial-talus articular surfaces of patients III:1 and III:2 (Fig. 2).

Echocardiography

Patient III:2 had Stage 1 aortic valve insufficiency. All patients (III:1 – 65%, III:2 – 66%, III:3 – 69%) had normal left ventricular ejection fraction as determined by Teichholz and normal blood pressure.

Electromyography

Needle electromyography demonstrated a myopathic pattern.

Genetic testing

Sequencing of Patient III:1, III:2 and III:3 DNA samples established a new homozygous mutation chr21:47402679T>C, leading to a change in the second intron canonical splice site (c.227 + 2T>C) in the COL6A1 gene. Sanger sequencing showed that the proband’s mother (II:2) is a carrier of heterozygous (c.227 + 2T>C) in the COL6A1 gene.

Dermal fibroblast culture

All patients had an abnormal collagen VI secretion by dermal fibroblasts, with severe to completely absent assembled matrix, associated with stained single extracellular microfibrils and intracellular retention of collagen VI precursors. (Fig. 3).

There was a reduced CFE-F in all patients – by 30% in Patient III:1, by 35% in Patient III:2 and by 32% in Patient III:3 when compared to the control (45–49%) [26]. Reduced CFE-F indicates decreased fibroblast precursor cell counts in the patient’s fibroblasts and decreased regenerative potential of the dermal fibroblast population.

Patients III:2 and III:3 had a normal proliferation index, while it being slightly below the normal in Patient III:1. A decreased proliferative index indicates a low mitotically active cell count in the culture, and hence a decreased regeneration rate in Patient III:1.

mRNA analysis

mRNA analysis in all patients revealed exon 2 skipping containing 130 bp, coding for the beginning of the N1-domain. The skip results in an out-of-frame transcript. We also detected full length transcripts at low percentage (III:1 – 5.4%; III:2 – 6.6%; III:3 – 6.5%). Thus, the homozygous mutation in the COL6A1 gene leads to a «leaky» out-of-frame skip of mRNA with synthesis allowing for the generation of a small percentage of full length transcript expected to generate wild type protein.

DISCUSSION

Two out of three siblings (48 and 53 years old) had severe contractures of the proximal joints and might most closely corresponded to an intermediate phenotype of collagen VI-related dystrophies (or the milder end of the “moderate progressive” phenotype of Brinas et al. [11], because both patients were able to walk independently up to 7–8 years, followed by the ineffective use of crutches and the beginning of walking on bent legs due to progressive contractures, but relatively better preserved muscle strength [34]. The eldest one had BTHLM with spinal rigidity, in some aspects reminiscent of the myosclerosis phenotype described previously as caused by a homozygous nonsense COL6A2 mutation (p.Q819X) [7]. The coexistence of divergent phenotypes in siblings of the same family has been previously recognized in the COL6-related dystrophies [8]. Genetic analysis was not possible for patient III:12 (2.5 y.o.) due to his early death; however, he probably also had collagen VI-associated dystrophy, as he had an early-onset pronounced proximal joint contracture and distal hypermobility. Patient III:11 (8 m.o.) cannot be classified due to his early death from a respiratory failure, but hypotonia and distal hypermobility suggest the same disease.

It is noteworthy to highlight that patients aged 48 (III:1) and 53 (III:2) years could walk with bent knee and hip joints for 35–40 years, indicating that upright ambulation was predominantly impaired by contractures rather than diffuse weakness and attesting to considerable adaptive capabilities of these patients and their musculoskeletal system.

This family also highlights the considerable variability in the degree of joint contractures even with the same underlying collagen VI mutation. The mechanism of joint contractures in the collagen VI-related dystrophies is still not fully explored and might reside within the muscle connective tissue, but also in tendon and joint capsules. Clearly there must be additional genetic modifiers determining the extend of such contractures.
Fig. 3. Collagen VI immunofluorescence in UCMD dermal fibroblasts (permeabilised (A) and non-permeabilised (B) conditions according to Hicks et al. (2008); CTRL – normal control, which has an abundance of well-organized collagen VI microfibrils showing a linear and unidirectional trend; III:1, III:2, III:3 – significant collagen VI rarefaction with stained single extracellular microfibrils and intracellular protein retention were noticed in most cells. Dermal fibroblasts immunostained for matrix-deposited collagen VI (red) and with the nuclear stain DAPI (blue). Scale bar 50 μm.

Despite considerable muscle atrophies in the upper limbs of siblings moving with the bent knee and hip joints (Patients III:1, III:2), there was hypertrophy of the posterior thigh muscles and some anterior thigh muscles (m. vastus lateralis, m. rectus femoris) in the lower extremities. Findings on muscle MR were consistent with a collagen VI related dystrophy (peri-fascial involvement) and there were diffuse lesions...
in muscles that appeared hypertrophied [30, 32]. Partial sparing of the contractile properties of myofibers within an otherwise affected muscle might help account for these adaptive capabilities of skeletal muscles. In context of an otherwise severely contractual phenotype [35], this may be allowing for the functional compensation seen in the siblings.

It is of interest that in this family the pulmonary function was relatively better preserved, compared to the functional severity of the skeletal muscle involvement. If the patients were within the UCMD phenotype one would have predicted earlier need for non-invasive ventilation latest at beginning of the second decade of life as previously reported [34, 36]. This supports our functional classification of the family in the intermediate to Bethlem range with less pulmonary involvement but with a considerable contractual phenotype. Therefore, restrictive changes of the chest, may be in part independent on the severity of proximal joint contractures [37]. Three patients described did not obviously require non-invasive ventilation as he has adapted to physical activity without a wheelchair in high altitudes. However, a nocturnal polysomnography will be needed to fully assess his sleep oxygenation and possibility for CO2 retention.

The newly described homozygous chr21:47402679T>C mutation in the COL6A1 gene results in a change in the canonical splice donor site of the second intron (c.227 + 2T>C), is likely to lead to the destruction of the splice site and the formation of an aberrant transcript with an out-of-frame skip of exon 2. In all patients described semi-quantitative PCR of fibroblast mRNA found a significant predominance of this aberrant transcript (93.4, 93.5 and 94.6%) which did not undergo a nonsense-mediated decay, but also confirmed the presence of full length wild type transcripts, presumably allowing for the production of some normal collagen VI. However, the predominant synthesis of severely truncated α1(VI) results in severe rarefaction of extracellular microfibers and diffuse intracellular accumulation of type VI collagen.

Fig. 4. Skipping of exon 2 in COL6A1. Schematic representation of mutation effect on “leaky” splicing, which allows generating some normal transcripts and significant amount of mutant transcript with deletion of 2 exon having a size of 130 bp in patient (A); scheme of normal full-length (1028 aa) and mutant protein α1 (VI) 103 aa; SP – signal peptide; TH – triple helical domain; C1–C2 -terminal domains (B); RT-PCR gel showing an additional faster migrating band in the patient lanes (III:1; III:2; III:3), but not in the normal controls (C1, C2) (C); sequencing chromatogram of cDNA representing the upper normal band (top) and lower band in patient III:1, III:2, III:3 revealing the loss of sequence corresponding to exon 2. RPLP0 was used as reference gene (bottom) (D).
precursors, detected in an immunofluorescence assay of permeabilised dermal fibroblasts. Thus, the mutation is "leaky" and therefore consistent with the overall milder presentation in this family compared to a full "null" situation, which would be predicted to result in a severe UCMD phenotype. However, we found no significant differences in the percentage of normal transcript formation among patients, to account for the milder phenotype in Patient III:3. In addition, all siblings had equally reduced fibroblast colony formation efficacy, which might suggest a genetically determined decrease of fibroblast progenitor cell counts, irrespective of the phenotype. While our findings appears to be in contrast to a previously reported correlation between a disease severity, the mutation type and the degree of decrease in collagen synthesis by fibroblasts [18, 38] it is possible that there are variations in the levels of normal collagen VI matrix formation in vivo in muscle and tendons that are not reflected in our in vitro assays.

CONCLUSION

This family observation demonstrates intrafamilial phenotypic and functional variability of collagen VI-related dystrophy presenting on the intermediate to Bethlem spectrum in patients with particularly pronounced differences in the contractual manifestations of the disease. It is caused by a newly described homozygous COL6A1 out-of-frame exon 2 skipping splice mutation. We demonstrate its leakiness allowing for the generation of some normal transcript. While the analysis on mRNA, collagen VI matrix secretion and proliferative ability did not reveal obvious differences that would explain the cause of intrafamilial phenotypic variability, more subtle differences in the degree of normal matrix deposition in vivo as well as the presence of yet to be identified genetic modifiers may be responsible for the variability observed in this family.

ACKNOWLEDGMENTS

The authors are grateful to E.A. Pomerantseva, the head of «GeneticO» laboratory (Moscow), and her employees (genetic testing).

CONFLICT OF INTEREST

The authors have no conflict of interest to report.

REFERENCES

[1] Allamand V, Brinas L, Richard P, Stojkovic T, Quijano-Roy S, Bonne G. ColVI myopathies: Where do we stand, where do we go? Skelet Muscle. 2011;1:30. doi:10.1186/2044-5040-1-30

[2] Bonnemann CG. The collagen VI-related myopathies: muscle meets its matrix. Nat Rev Neurol. 2011;7:379-90. doi:10.1038/nrneurol.2011.81

[3] Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: In-depth analysis of a muscle clinic population. Brain. 2009;132:3175-86. doi:10.1093/brain/awp236

[4] Okada M, Kawahara G, Noguchi S, Sugie K, Murayama K, Nonaka I, Hayashi YK, Nishino I. Primary collagen VI deficiency is the second most common congenital muscular dystrophy in Japan. Neurology. 2007;69:1035-42. doi:10.1212/01.wnl.0000271387.10404.4e

[5] Ullrich O. Kongenitale, atonisch-sklerotische Muskeldystrophie, ein weiterer Typus der heredodegenerativen Erkrankungen des neuromuskulären Systems. Zeitschrift für die gesamte Neurologie und Psychiatrie. 1930:126:171-201. doi:10.1007/bf0234097

[6] Scacheri PC, Gillanders EM, Subramony SH, Veda-narayan V, Crowe CA, Thakore N, Binger M, Hoffman EP. Novel mutations in collagen VI genes: Expansion of the Bethlem myopathy phenotype. Neurology. 2002;58:593-602. doi:

[7] Merli L, Mattioni E, Grumati P, Sabatelli P, Squarzoni S, Urciuolo A, Fèrlini A, Gualandri F, Bonaldo P. Autosomal recessive myosclerosis myopathy is a collagen VI disorder. Neurology. 2008;71:1245-53. doi:10.1212/01.wnl.0000327611.01687.5e

[8] Bonnemann CG. The collagen VI-related myopathies. Ul-lich congenital muscular dystrophy and Bethlem myopathy. Handb Clin Neurol. 2011;101:81-96. doi:10.1016/b978-0-08-045031-5.00005-0

[9] Lampe AK, Bushby KM. Collagen VI related muscle disorders. J Med Genet. 2005;42:673-85. doi:10.1136/jmg.2002.02311

[10] Bradley WG, Hudgson P, Gardner-Medwin D, Walton JN. The syndrome of myosclerosis. J Neurol Neurosurg Psychiatry. 1973;36:651-60. doi:10.1136/jnnp.36.4.651

[11] Brinas L, Richard P, Quijano-Roy S, Gurtoux C, Ledueil C, Lacene E, Makri S, Ferreiro A, Maugenre S, Topaloglu H, Haliloglu G, Penisson-Besnier I, Jeannet PY, Merlini L, Navarro C, Toutain A, Desgreneur I, de Die-Smulders C, Dunand M, Echenne B, Eymard B, Kuntzer T, Maincent K, Mayer M, Plessis G, Rivier F, Roelens S, Tranchant C, Viollet L, Romero NB, Estournet B, Guich-enev P, Allamand V. Early onset collagen VI myopathies: Genetic and clinical correlations. Ann Neurol. 2010;68:511-20. doi:10.1002/ana.22087

[12] Foley AR, Hu Y, You Y, Yang M, Medne L, Leach M, Conlin LK, Spinner N, Shaikh TH, Falk M, Neumeyer AM, Bliss L, Tseng BS, Winder TL, Bonnemann CG. Large genomic deletions: A novel cause of Ulrich congenital muscular dystrophy. Ann Neurol. 2011;69:206-11. doi:10.1002/ana.22283

[13] Weil D, Mattei MG, Passage E, N’Guen VC, Pribula-Conway D, Mann K, Deutzmann R, Timpl R, Chu ML. Cloning and chromosomal localization of human genes encoding the three chains of type VI collagen. Am J Hum Genet. 1988;42:435-45. doi:
of human skin fibroblasts in relation to cellular senescence and proliferation. Aging (Albany NY). 2017;9:1404-13. doi:10.18632/aging.101240

[27] Е.Б. Владимирская and И.В. Кошель, Стромальные фиброblastы нормального жирового мозга у детей., Генетология и трансфузиология. 1990, 3-5. doi

[28] Hicks AKLD, Barresi R, et al. A refined diagnostic algorithm for Bethlem myopathy. Neurology. 2008;1192-9. doi:10.1212/01.wnl.0000307479.66438.6d

[29] James WP, Mascie-Taylor GC, Norgan NG, Bistrian BR, Shetty PS, Ferro-Luzzi A. The value of arm circumference measurements in assessing chronic energy deficiency in Third World adults. Eur J Clin Nutr. 1994;48:883-94. doi

[30] Mercieri E, Lampe A, Allsop J, Knight R, Pane M, Kiniali M, Bonnemann C, Flanigan K, Lapini I, Bushby K, Pepe G, Muntoni F. Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathy. Neuromuscul Disord. 2005;15:303-10. doi:10.1016/j.nmd.2005.01.004

[31] Deconinck N, Richard P, Allamand V, Behin A, Lafortet P, Ferreira A, de Becdelievre A, Ledeuil C, Gauthier C, Nelson I, Carlier RY, Carlier P, Wabili K, Romero N, Zobet MT, Bouhour F, Tiffreau V, Lacour A, Eymard B, Stojkovic T. Bethlem myopathy: Long-term follow-up identifies COL6 mutations predicting severe clinical evolution. J Neurol Neurosurg Psychiatry. 2015;86:1337-46. doi:10.1136/jnnp-2013-307245

[32] Fu J, Zheng YM, Jin SQ, Yi JF, Liu XY, Hsing WC, Zhang W, Xiao JX, Yuan Y. “Target” and “Sandwich” Signs in Thigh Muscles have High Diagnostic Values for Collagen VI-related Myopathies. Chin Med J (Engl). 2016;129:1811-6. doi:10.4103/0366-6999.186638

[33] Mercieri E, Cini C, Counsell S, Allsop J, Zuckl K, Jungbluth H, Sewry C, Brown SC, Pepe G, and Muntoni F. Muscle MRI findings in a three-generation family affected by Bethlem myopathy. Eur J Paediatr Neurol. 2002;6:309-14. doi

[34] Foley AR, Quijano-Roy S, Collins J, Straub V, McLum M, Deconinck N, Mercieri E, Pane M, D’Amico A, Bertini E, North K, Ryan MM, Richard P, Allamand V, Hicks D, Ledeuil S, Yu Y, Gauthier C, Auh S, Muntoni F, Bonnemann CG. Natural history of pulmonary function in collagen VI-related myopathies. Brain. 2013;136:3625-33. doi:10.1093/brain/aws284

[35] Blauw B, Agatea L, Toniole L, Canato M, Quarta M, Dyar KA, Danieli-Bette D, Betto R, Schiaffino S, Reggiani C. Eccentric contractions lead to myofibrillar dysfunction in muscular dystrophy. J Appl Physiol. 1985;10(10):105-11. doi:10.1152/japplphysiol.00803.2009

[36] Quijano-Roy S, Khirane S, Coloea M, Ramirez A, Aloui S, Wehbi S, de Becdelievre A, Carlier RY, Allamand V, Richard P, Azzi V, Estournet B, Fauroux B. Diaphragmatic dysfunction in Collagen VI myopathies. Neuromuscul Disord. 2013;23:15-22. doi:10.1016/j.nmd.2013.01.001

[37] Nadeau A, Kinali M, Main M, Jimenez-Mallebrera C, Alosysius A, Clement E, North B, Manzur AY, Robb SA, Mercieri E, Muntoni F. Natural history of Ullrich congenital muscular dystrophy. Neurology. 2009;73:25-31. doi:10.1212/WNL.0b013e3181aee851

[38] Hicks D, Lampe AK, Barresi R, Charlton R, Fiorillo C, Bonnemann CG, Hudson J, Sutton R, Lochmuller H, Straub V, Bushby K. A refined diagnostic algorithm for Bethlem myopathy. Neurology. 2008;70:1192-9. doi:10.1212/01.wnl.0000307479.66438.6d

[39] Blauw B, Bogaard B, Toniole L, Canato M, Quarta M, Dyar KA, Danieli-Bette D, Betto R, Schiaffino S, Reggiani C. Eccentric contractions lead to myofibrillar dysfunction in muscular dystrophy. J Appl Physiol. 1985;10(10):105-11. doi:10.1152/japplphysiol.00803.2009

[40] Quijano-Roy S, Khirane S, Coloea M, Ramirez A, Aloui S, Wehbi S, de Becdelievre A, Carlier RY, Allamand V, Richard P, Azzi V, Estournet B, Fauroux B. Diaphragmatic dysfunction in Collagen VI myopathies. Neuromuscul Disord. 2013;23:15-22. doi:10.1016/j.nmd.2013.01.001

[41] Nadeau A, Kinali M, Main M, Jimenez-Mallebrera C, Alosysius A, Clement E, North B, Manzur AY, Robb SA, Mercieri E, Muntoni F. Natural history of Ullrich congenital muscular dystrophy. Neurology. 2009;73:25-31. doi:10.1212/WNL.0b013e3181aee851

[42] Hicks D, Lampe AK, Barresi R, Charlton R, Fiorillo C, Bonnemann CG, Hudson J, Sutton R, Lochmuller H, Straub V, Bushby K. A refined diagnostic algorithm for Bethlem myopathy. Neurology. 2008;70:1192-9. doi:10.1212/01.wnl.0000307479.66438.6d

[43] Blauw B, Bogaard B, Toniole L, Canato M, Quarta M, Dyar KA, Danieli-Bette D, Betto R, Schiaffino S, Reggiani C. Eccentric contractions lead to myofibrillar dysfunction in muscular dystrophy. J Appl Physiol. 1985;10(10):105-11. doi:10.1152/japplphysiol.00803.2009

[44] Quijano-Roy S, Khirane S, Coloea M, Ramirez A, Aloui S, Wehbi S, de Becdelievre A, Carlier RY, Allamand V, Richard P, Azzi V, Estournet B, Fauroux B. Diaphragmatic dysfunction in Collagen VI myopathies. Neuromuscul Disord. 2013;23:15-22. doi:10.1016/j.nmd.2013.01.001

[45] Nadeau A, Kinali M, Main M, Jimenez-Mallebrera C, Alosysius A, Clement E, North B, Manzur AY, Robb SA, Mercieri E, Muntoni F. Natural history of Ullrich congenital muscular dystrophy. Neurology. 2009;73:25-31. doi:10.1212/WNL.0b013e3181aee851

[46] Hicks D, Lampe AK, Barresi R, Charlton R, Fiorillo C, Bonnemann CG, Hudson J, Sutton R, Lochmuller H, Straub V, Bushby K. A refined diagnostic algorithm for Bethlem myopathy. Neurology. 2008;70:1192-9. doi:10.1212/01.wnl.0000307479.66438.6d

[47] E.B. Владимирская and И.В. Кошель, Стромальные фиброblastы нормального жирового мозга у детей., Генетология и трансфузиология. 1990, 3-5. doi